Ipsen's Corabotase Shows Rapid, Long-Lasting Wrinkle Reduction in Phase II Trial

17 May 2026 news

What we know

Ipsen has unveiled promising Phase II clinical trial results for Corabotase, a novel treatment targeting moderate-to-severe glabellar lines (wrinkles between the eyebrows). According to data presented at the 2026 Scale Symposium in Nashville, TN, Corabotase demonstrated a rapid onset of action, with patients experiencing visible wrinkle reduction in just 0.84 days on average. The treatment's effects were sustained for up to 24 weeks (approximately six months), with 60.8% of patients showing clinically significant improvement at Week 24 compared to placebo.

Corabotase is Ipsen's first-in-class recombinant neuroinhibitor designed to reduce wrinkles by modulating muscle activity in the targeted area. The Phase II trial included 183 patients and showed a peak effect that was statistically superior to placebo, reinforcing both the efficacy and durability of the treatment. Patient satisfaction was consistently high throughout the study period, highlighting the potential appeal of Corabotase in aesthetic medicine.

Why it matters

The rapid onset and sustained duration of Corabotase's effects represent a significant advancement in wrinkle treatment options. Current wrinkle treatments often require several days to weeks before visible results appear and may necessitate frequent retreatments to maintain effects. Corabotase's ability to deliver noticeable wrinkle reduction in less than a day and maintain results for six months challenges existing standards in the aesthetic field.

This breakthrough could reshape patient expectations and clinical practices, offering a more convenient and longer-lasting alternative. High patient satisfaction rates suggest that Corabotase may improve quality of life for individuals seeking non-invasive cosmetic solutions. However, the rapid onset and long duration also raise important questions about accessibility, cost, and long-term safety that will need to be addressed as the treatment progresses through regulatory review and potential commercialization.

What happens next

Following the successful Phase II trial, Ipsen is expected to advance Corabotase into later-stage clinical trials to further evaluate its safety and efficacy across larger and more diverse patient populations. Regulatory submissions will be a critical next step before the treatment can be made widely available. Ongoing monitoring of long-term outcomes and side effects will be essential to ensure patient safety given the novel mechanism and sustained duration of action.

Meanwhile, the aesthetic medicine community will be closely watching how Corabotase compares to existing wrinkle treatments in terms of cost-effectiveness, accessibility, and patient preference. The potential for Corabotase to become a new standard of care depends on these factors as well as regulatory approvals.

Key takeaways

Corabotase showed a rapid onset of wrinkle reduction in 0.84 days.
Effects lasted up to 24 weeks, significantly longer than many current treatments.
60.8% of patients experienced clinically significant improvement at 24 weeks.
High patient satisfaction was reported throughout the trial.
Further clinical trials and regulatory review are needed before market availability.

FAQ

What is Corabotase?

Corabotase is a first-in-class recombinant neuroinhibitor developed by Ipsen to reduce moderate-to-severe glabellar lines by modulating muscle activity.

How quickly does Corabotase work?

Patients in the Phase II trial experienced visible wrinkle reduction in an average of 0.84 days after treatment.

How long do the effects last?

The treatment effects lasted up to 24 weeks (approximately six months) with 60.8% of patients maintaining clinically significant improvement at Week 24.